Alexion Pharmaceuticals, Inc. ALXN shares are down 23.5 percent in the past month as investors have grown concerned about the growth outlook for Solaris and the implications of the company’s management shuffling. At this point, market pessimism has gotten so high that the absence of negative headlines could be the stock’s next catalyst, UBS analyst Martin Auster said in a new note.
A Brightening Horizon
“Without clear emerging evidence of fundamental weakness (we think the company would have lowered 2017 guidance in ALXN’s recent management changes presser if that were on the table), an absence of a ‘next shoe’ may be enough to stabilize shares,” Auster said.
At this point, Alexion’s risks are fully reflected in the stock’s valuation, Auster said. These risks include an increase in discount rate from 10 percent to 12 percent, a 25 percent reduction in PNH/aHUS growth rate through 2021 (from 9 percent to 7 percent) and the complete failure of ALXN1210, Soliris-gMG and Soliris-NMO. The market is currently pricing in a 35 percent probability of success for ALXN1210 and a 0 percent probability of success for Soliris-gMG and Soliris-NMO, Auster said.
UBS projects gMG and NMO could add a combined $1.5 billion in peak sales if approved. In addition, the firm projects that ALXN1210 will draw 50 percent of the new PNH and aHUS patient market share by 2021. UBS also projects $1 billion in annual Strensiq sales by 2023.
Assuming the company can gain traction with several of its main projects, management will likely focus on cost-cutting in years ahead, Auster said. Alexion’s R&D budget ballooned…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
